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Abstract:
BACKGROUND: The first cases of the coronavirus disease 2019 (COVID‑19) were reported in
Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy.
However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe
treatment option for COVID‑19 patients with both moderate and severe disease.
OBJECTIVE: The aim of the present meta‑analysis was to investigate whether remdesivir was
effective for treating COVID‑19 including reduced in‑hospital adverse events, oxygen support, and
mortality rates.
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METHODS: According to the PRISMA reporting guidelines, a review was conducted from
January 1, 2020, until August 25, 2020, with MeSH terms including COVID‑19, COVID, coronavirus,
SARS‑CoV‑2, remdesivir, adenosine nucleoside triphosphate analog, and Veklury using MEDLINE,
Scopus, and CINAHL Plus. A modified Delphi process was utilized to include the studies and ensure
that the objectives were addressed. Using dichotomous data for select values, the unadjusted odds
ratios (ORs) were calculated applying Mantel–Haenszel random‑effects method in Review Manager 5.4.
RESULTS: Randomized controlled trials pooled in 3013 participants with 46.3% (n = 1395) in the
remdesivir group and 53.7% (n = 1618) in the placebo group. The placebo group had a higher risk of
mortality as compared to the intervention group with significant OR (0.61) (95% confidence interval
of 0.45–0.82; P = 0.001). There was minimal heterogeneity among the studies (I2 = 0%).
CONCLUSIONS: Our findings suggest that remdesivir extends clinical benefits by reducing mortality,
adverse events, and oxygen support in moderate to severely ill COVID‑19 patients. Concerted efforts
and further randomized placebo‑controlled trials are warranted to examine the potency of antiviral
drugs and immunopathological host responses contributing to the severity of COVID‑19.
Keywords:
Coronavirus, emergency use authorization, hospitalized, remdesivir, Veklury

Introduction

S

ince the first cases of the coronavirus
disease 2019 (COVID‑19) were reported in

This is an open access journal, and articles are
distributed under the terms of the Creative Commons
Attribution‑NonCommercial‑ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work
non‑commercially, as long as appropriate credit is given and
the new creations are licensed under the identical terms.
For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.
com

Wuhan, Hubei Province, China, in December
2019, a large‑scale spread internationally
led the World Health Organization (WHO)
to declare COVID‑19 as a public health
emergency of international concern on
January 30, 2020.[1] Antiviral treatment options
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Box‑ED
What do we know about remdesivir (Veklury) for
coronavirus disease 2019 so far?

• Remdesivir is an antiviral drug, which has shown
promise in randomized controlled trials for
coronavirus disease 2019 (COVID-19)
• The extended emergency use authorization by the
US Food and Drug Administration has promoted
its use among hospitals in the US and worldwide.
Why is this important for readers?

• The role of remdesivir as an experimental drug has
been promising during the COVID-19 pandemic
• The drug will likely to be the best antiviral choice of
treatment for all moderate and severe SARS-CoV-2
infections.
How is this study structured?

• This is a meta-analysis study which includes
data from 3013 patients who were administered
remdesivir for 5 and 10 days.
What does this study inform us about?

• Remdesivir extends clinical benefits in hospitalized
patients by reducing mortality, adverse events, and
the requirement for oxygen support
• Ongoing efforts are required by conducting randomized
placebo-controlled trials across the world.
• The potency of the antiviral drug, remdesivir, must be
examined along with testing immunopathological
host responses contributing to the severity of
COVID-19.
of proven clinical efficacy in COVID‑19 infections are
under investigation.[2] Remdesivir is an investigational
nucleotide prodrug which intracellularly metabolizes
to the active nucleoside triphosphate and interferes
with viral RNA‑dependent RNA polymerase activity,
thereby disrupting viral exoribonuclease activity.[3]
However, the pharmacokinetics of remdesivir within
the respiratory tract of critically ill COVID‑19 patients
are not well known. Hospitalized COVID‑19 patients
with oxygen saturation ≤94% on room air or requiring
oxygen support are eligible to receive remdesivir under
the US Food and Drug Administration (FDA) emergency
use authorization (EUA).[4] While previous studies have
reported a reduction in median time to clinical improvement,
insufficient power of sample sizes limited the deductibility
of clinical outcomes of remdesivir.[5] In addition, initiating
remdesivir earlier in the COVID‑19 treatment protocols
must be considered before immune‑mediated epithelial
damage due to the fact that elevated viral replication occurs
and may reduce mortality and disease severity as observed
previously in severe acute respiratory syndrome (SARS)
and Middle East respiratory syndrome (MERS).[6]
Based on the preliminary reports and findings from
in vitro and in vivo activity in animal models of
44

SARS‑CoV‑1 and MERS‑CoV, remdesivir treatment for
5 or 10 days is being administered to COVID‑19 patients
with comparable efficacy and safety.[7‑9] While most
COVID-19 infections are self-limiting, some individuals
may contract severe disease warranting increased length
of hospital stay and ventilator support, which places
burden on health infrastructures.[10] Use of remdesivir
has resulted in reduced oxygen support in a cohort with
53 hospitalized COVID‑19 patients.[11] Consequently,
with revised recommendations suggesting uncertain
efficacy of remdesivir and benefits among patients
already on high‑flow oxygen, mechanical ventilation,
or extracorporeal membrane oxygenation (ECMO), the
initiation and duration of remdesivir treatment among
COVID‑19 hospitalized patients receiving oxygen support
remain unclear.[12] Given the uncertainty on the beneficial
outcomes of remdesivir‑treated COVID‑19 patients, we
aimed to examine the following differences between
remdesivir and placebo groups: (1) oxygen support status
at day 1 and day 14, (2) any adverse events at day 14,
and (3) death from any cause at day 14.

Methods
Search strategy

According to the PRISMA reporting guidelines, a review
was conducted from January 1, 2020, until August 6, 2020,
with MeSH terms including “COVID‑19,” “coronavirus,”
“SARS‑CoV‑2,” “COVID,” “remdesivir,” “adenosine
nucleoside triphosphate analog,” “Veklury” using
Medline, Scopus, and CINAHL Plus. Quantitative primary
research articles were added to the systematic review
and meta‑analysis. The inclusion criteria of the included
studies were having COVID‑19–infected patients aged 18
or older being treated with remdesivir and/or placebo.
Duplicates were removed using EndNote X9 a reference
management software package developed by Clarivate
Analytics. We manually cross‑checked the searches for
authors, title, and abstract to remove duplicates.
Two investigators (AS and ZS) independently
screened the titles and abstracts before reaching to a
consensus to determine the included studies. The third
investigator (MSG) was present for any disagreements.
Exclusion criteria were applied to full texts during the
final selection. A modified Delphi process was used to
include studies and to ensure that our objective was
identified in selected studies .[13] The a priori methods
for conducting the Delphi process for meta‑analyzing
the clinical effectiveness are described in Figure 1. We
included studies if they were randomized control trials,
they had an intervention arm as compared to placebo,
and the end point of interest was clinical outcomes and
mortality. Two investigators (AS and ZS) re‑confirmed
all data entries and checked imported data from all
studies at least thrice for accuracy.
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We independently extracted data from the published
randomized placebo‑controlled trials.
Using dichotomous data for select values, summary
measures namely the unadjusted odds ratios (ORs) were
calculated using the Mantel–Haenszel random‑effects
methods. We calculated the ORs and 95% confidence
intervals (CIs) for each measure evaluated in two or more
studies. A meta‑analysis was conducted using Review
Manager V.5.4 the desktop version of the software
used for review formats (diagnostic, methodology,
overviews), for non-Cochrane reviews, and for offline
working, developed by Cochrane Training. Findings
were presented using 95% CIs along with the I2 test for
heterogeneity between studies.

Source of funding

No funding was obtained for the purpose of this study.

Results
Figure 1: Modified Delphi Process

Quality assessment

We evaluated the risk of bias for all included studies
using the Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) criteria.[14]
We aimed to evaluate the risk of bias associated with
the selection of participants, confounding, and health
outcome assessment. In doing so, we found the risk
of bias of all four individual studies included for
quantitative analysis using the GRADE criteria. Since
less than 10 studies were included, we did not check for
publication bias using funnel plots.

The search process is shown in Figure 2. The initial
screening yielded 1242 results. After the exclusion of
duplicates, 946 results were withheld for the screening
of title and abstract. Consequently, 704 records were
excluded due to ineligibility (reviews, editorials,
non‑random controlled trials, ongoing trials, and
abstracts). Finally, after screening 242 full‑text articles,
only four studies reporting 3013 patients (remdesivir
n = 1395; placebo n = 1618) were included in the
qualitative and quantitative syntheses. While three out
of four studies were of high quality based on the GRADE
scale, Olender et al.’s study was graded moderate.[15]

Mortality at day 14 of treatment

The primary outcomes included death from any cause
at day 14. The secondary outcomes were to identify
any adverse events at day 14 of the treatment and the
requirement for supplemental oxygen, high‑flow nasal
cannula, noninvasive ventilation, invasive ventilation,
or ECMO at day 1 and 14. The time to recovery in days,
total patients recovered, and findings of serious adverse
effects among remdesivir and placebo groups were
identified.

All four studies reported the data on mortality at day 14
and thus were eligible to be included in the meta‑analysis.
Compared with the remdesivir‑treated group, the
placebo group had higher risks of mortality (OR: 0.61;
95% CI: 0.45–0.82; P = 0.001) [Figure 3]. For the sensitivity
analysis, we tested if the removal of study by Beigel
et al. would lead to changes in the OR and significance.
After excluding this study, the results suggested that the
risk of mortality was still higher in the placebo group
(OR: 0.66; 95% CI: 0.44–0.98; P = 0.04), with homogenous
findings (I2 = 0%).

Data analysis

Supplemental oxygen at day 1 and 14 of treatment

Outcomes

Two independent reviewers (AS and ZS) assessed
the eligibility of all full‑text articles; the third (MSG)
arbitrated for cases to reach a consensus. The first
reviewer (AS) extracted the data, and the second
reviewer (ZS) validated the data extraction for all studies.
The quantitative data were entered into a spreadsheet.
If more than one study reported data on posttreatment
outcomes, data were extracted separately for each study.

All four studies presented the data of supplemental
oxygen requirement at day 1 of treatment among the
remdesivir and placebo groups. Using a random‑effects
model, we determined that the remdesivir group
had similar odds as compared to the placebo group
in requiring supplemental oxygen at the 1st day of
treatment (OR: 1.03; CI: 0.87–1.23; P = 0.70), with limited
heterogeneity among all studies (I2 = 8%) [Figure 3].
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Figure 2: PRISMA flowchart

Three out of four studies evaluated the supplemental
oxygen use at day 14 of the treatment among the
remdesivir group and the placebo group. However,
there was a higher likelihood of the placebo group to
require supplemental oxygen at the end of the 2nd week
of treatment (OR: 0.88; CI: 0.62–1.24; P = 0.46), with no
heterogeneity among the studies (I2 = 1%) [Figure 3].

High‑flow nasal cannula or noninvasive
mechanical ventilation at day 1 and 14 of
treatment
All four studies presented the data of high‑flow nasal
cannula or noninvasive mechanical ventilation required
at day 1 of treatment. Patients in the placebo group
as compared to the remdesivir group had high odds
of requiring high‑flow nasal cannula or noninvasive
mechanical ventilation (OR: 0.81; CI: 0.64–1.04; P = 0.10;
I2 = 9%) [Figure 3].
Three of the four studies presented the requirements
of high‑flow nasal cannula or noninvasive
mechanical ventilation at day 14 of treatment.
The likelihood of the placebo group was higher
46

as compared to the remdesivir group of requiring
intervention (OR: 0.90; CI: 0.53–1.53; P = 0.69), with no
heterogeneity among the studies (I2 = 0%) [Figure 3].

Invasive ventilation or extracorporeal membrane
oxygenation at day 1 and 14 of the treatment
Three of the four studies presented the data of invasive
ventilation or ECMO at the 1 st day of treatment.
While the difference was negligible, there was a
very slight preponderance of the remdesivir group
to require invasive ventilation or ECMO at day 1
of the treatment (OR: 1.06; CI: 0.73–1.54; P = 0.77;
I2 = 28%) [Figure 3].
Three of the four studies reported the data on invasive
ventilation or ECMO at day 14 of the treatment. Patients
in the placebo group had a higher likelihood of requiring
invasive ventilation or ECMO at the 2nd week of the
treatment as compared to the patients in the remdesivir
group (OR: 0.39; CI: 0.13–1.14; P = 0.09) [Figure 3]. There
was moderately high heterogeneity among the studies
included for the analysis (I2 = 62%).
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Figure 3: Forrest plots of primary and second outcomes
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Overall serious adverse events after initiation of
treatment

Three of the four studies reported the data on the
overall serious adverse effects initiation of treatment,
and thus, they were included in the meta‑analyses.
The placebo group had a higher risk or likelihood
of presenting with adverse outcomes as compared
to the remdesivir group but with less statistical
significance (OR: 0.75; CI: 0.55–1.02; P = 0.07) [Figure 3]. There
was mild heterogeneity between the studies (I2 = 26%).

Discussion
The purpose of the study was to comprehensively
review the efficacy of remdesivir compared to placebo
among hospitalized patients with moderate and severe
COVID‑19. Our inclusion criteria, determined by the
input of all panel members, were specific for adult
hospitalized COVID‑19 patients treated with either
remdesivir or placebo, which distinguishes the findings
from other meta‑analyses. Based on the analysis of
four randomized placebo‑controlled trials, the overall
findings support the use of remdesivir to reduce oxygen
support, adverse events, and all‑cause mortality after
5 or 10 days of remdesivir treatment. [5,15,16] Overall,
the mortality rate for remdesivir‑treated patients
with COVID‑19 of the three included studies ranged
1.3%–10% as compared to the 2%–12.5% mortality rates
of the placebo‑treated patients. This findings were
consistent with recent clinical data reporting positive
outcomes for the compassionate use of remdesivir in
moderate and severe COVID‑19 patients.[11,13,14]
The time to clinical recovery was significantly lower among
patients who received remdesivir compared to placebo
across two studies (21 vs. 23 days and 11 vs. 15 days).
A randomized, open‑label, phase 3 three‑arm trial
including 584 patients with moderate COVID‑19
disease compared the efficacy of 5‑ and 10‑day courses
of remdesivir treatment, compared with standard care.
The median time to clinical recovery across the 5‑ and
10‑day treatment course was 6 and 8 days, respectively,
with recovery in the standard care group being 7 days.
There were observed differences in the requirements
of supplemental oxygen with the remdesivir group
requiring less supplemental oxygen at day 14 than
the placebo group with day‑1 data, demonstrating
significant use of supplemental oxygen in the remdesivir
group. While there was a very slight preponderance of
the remdesivir group to require the use of high‑flow
nasal cannula or noninvasive mechanical ventilation
at day 1, the remdesivir group had reduced likelihood
of being on invasive ventilation or ECMO at day 14.
Along with reduced overall oxygen support required
in the remdesivir group, the all‑cause mortality and
any adverse events were significantly reduced in
48

the remdesivir group in comparison to the placebo
group. An analysis of 138 healthy volunteers was
treated with remdesivir, and it appears to have a safe
clinical profile and is well‑tolerated with transaminase
elevation identified as the only adverse event.[17] Special
attention should be given to renal events, pregnancy,
hypersensitivity reactions, and concomitant vasopressor
use before remdesivir initiation.[17]
To the best of our knowledge, this is the first meta‑analysis
and systematic review of remdesivir and control groups,
which determines oxygen support status at day 1 and
14, any adverse events at day 14, and all‑cause mortality
at day 14. We synthesize various clinical outcomes of
interest using statistical analysis methods that are widely
applicable and relevant to key stakeholders in healthcare.
Our results demonstrate that remdesivir use in adults
may improve in-hospital mortality, oxygen support
status and adverse events within 2 weeks of treatment
initiation. Our findings synthesize the results of primary
and secondary outcomes of ongoing or completed
clinical trials.[18‑20] FDA’s press release on August 28,
2020, broadened the EUA for remdesivir (e.g., Veklury)
to include all hospitalized patients for the treatment
of COVID‑19. The scope of existing authorization is
based on the conclusions that remdesivir is an effective
treatment option for suspected or laboratory‑confirmed
COVID‑19 patients in hospitalized settings, with further
trials required to explore the efficacy according to the
clinical stratification.
We found over 35 trials registered on the ClinicalTrials.
gov classified as remdesivir group versus placebo group
using 200 mg loading dose on the 1st day, followed by
100 mg intravenous once‑daily doses for 5–10 days. The
outcomes of the ongoing trials are to determine the time
to clinical improvement, clinical status, time to hospital
discharge, all‑cause mortality, duration of mechanical
ventilation, ECMO, supplemental oxygen, length of
hospital stay, change in viral load assessed by area under
viral load curve, and the frequency of adverse events.
The baseline health and disease severity were not
matched in the remdesivir and placebo groups in our
included studies. In addition, the use of remdesivir
in high‑risk populations, e.g., elderly age, multiple
comorbidity, Blacks, and sociodemographic disparity,
may be considered before moderate or severe COVID‑19
manifestations occur.[21] The most adequate time of
administering antiviral treatment is soon after the
onset of disease to promote benefits, with previous
reports recommending initiation within 5 or 10 days
after the onset of symptoms.[14,22,23] Early results based
on the interim data may lack generalizability, but the
use of remdesivir has already obtained an approval for
EUA by the US FDA. The benefits of administrating
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remdesivir may outweigh the risks in hospitalized
COVID‑19 patients with oxygen saturation below 94%.
Patients who have been intubated for a short period
can also benefit from remdesivir dosage every 24–28 h.
However, limited clinical effectiveness is expected among
patients being mechanically ventilated.
In addition, the next steps in finding a consensus
toward remdesivir use follow the evaluation of potential
short‑term and long‑term side effects of remdesivir,
taking into consideration the concomitant use of other
medication. For instance, the off‑label use of medications
such as lopinavir–ritonavir, hydroxychloroquine, and
immunomodulatory drugs including glucocorticoids
and tocilizumab may confound reports of currently
promising and beneficial outcomes of remdesivir use.

Recommendations

Reporting biases of currently published trial results
may be taken into consideration. The clinical benefits
ought to be predicted within all severity subgroups to
confer rigorous support for clinical guidance toward
remdesivir. As the world strives to overcome structural
and social healthcare disparities, we must accentuate the
underrepresentation or lack of available data interpreting
the incidence and clinical outcomes of minority groups
in the remdesivir COVID‑19 trials.[24] In a preliminary
cohort study published by Grein et al., data of ethnicity
were omitted for 53 patients.[11] While the vetting for
preliminary results was obtained from limited datasets,
the proportion of Black, Latinx, and Native Americans
were around 20%, 23%, and 0.7% respectively, in trials
published by Beigel et al. and Goldman et al.[7,16] In
addition, while Asia’s population is roughly equivalent
to 60% of the world population, Spinner et al.’s trial only
consisted of 17.5% Asian participants.[14] The modest
benefits in time to clinical improvement post treatment
may not be generalizable in minority groups due to
probable differences in severity of disease, outcomes,
and treatment efficacy. The lack of ethnic diversity in
clinical studies during the COVID-19 pandemic ought
to be addressed at the administrative level by mandating
the inclusion of minority groups and reporting data at
the governmental level. A prioritization of populations
reflecting the demographics of high‑risk groups impacted
by the ongoing pandemic is crucial, by expanding clinical
trial sites and employing random sampling.[25]

Limitations

Our findings were limited due to a paucity of available
data between a 5‑day and a 10‑day course of intravenous
remdesivir treatment among severe and moderate
COVID‑19 patients, with only one randomized placebo
trial reporting these findings. All studies had open‑label
designs, which potentially led to biases in both patient
care and reporting of data. Another limitation was the

lack of corroboration of clinical efficacy with the viral
loads of the patients in both groups. While the biological
mechanisms of remdesivir are required to interpret the
clinical efficacy, not all studies reported the viral loads
in our meta‑analysis.

Conclusion
Our findings provide strong evidence of clinical
improvement in randomized, placebo‑controlled
trials of remdesivir therapy. Implications of our
meta‑analyses results are strong with a moderately large
sample size and randomized placebo group. Ongoing
placebo‑controlled trails employing larger sample sizes
will remain our informative source of the outcomes
and adverse events of remdesivir administered to
hospitalized COVID‑19 patients. Strategies must be used
to enhance the potency of remdesivir while reducing
the immunopathological host responses that contribute
to the infection severity. In addition, the efficacy of
5 versus 10 days dosing of remdesivir warrants further
exploration. Our findings suggest that remdesivir merits
extended clinical use and may also be efficacious among
nonsevere hospitalized COVID‑19 patients.
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